Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$95.15
-1.02-1.06%
al cierre: -
$95.15
0.000.00%
After hour: 4:29 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
HealthEquity Inc ha un obiettivo di prezzo di consenso pari a $116.72, stabilito in base alle ultime valutazioni degli analisti di 18. Le ultime 3 valutazioni degli analisti sono state rilasciate da Keybanc, Jefferies y JP Morgan il octubre 8, 2025, septiembre 3, 2025 y septiembre 3, 2025. Con un obiettivo di prezzo medio di $126.67 tra le Keybanc, Jefferies y JP Morgan, c'è un implicito 33.12% upside per HealthEquity Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Keybanc
Jefferies
JP Morgan
Barrington Research
RBC Capital
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para HealthEquity
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/08/2025 | 26.12% | Keybanc | $125 → $120 | Maintains | Overweight | |||
09/03/2025 | 40.83% | Jefferies | $130 → $134 | Maintains | Buy | |||
09/03/2025 | 32.42% | JP Morgan | $125 → $126 | Maintains | Overweight | |||
09/03/2025 | 31.37% | Barrington Research | $125 → $125 | Maintains | Outperform | |||
09/03/2025 | 15.61% | RBC Capital | $109 → $110 | Maintains | Outperform | |||
08/29/2025 | 31.37% | Barrington Research | $125 → $125 | Maintains | Outperform | |||
08/28/2025 | 14.56% | RBC Capital | $117 → $109 | Maintains | Outperform | |||
07/08/2025 | 26.12% | Raymond James | $115 → $120 | Reiterates | Strong Buy → Strong Buy | |||
06/11/2025 | 36.63% | Jefferies | $118 → $130 | Maintains | Buy | |||
06/05/2025 | 31.37% | Barrington Research | $112 → $125 | Maintains | Outperform | |||
06/05/2025 | 20.86% | Deutsche Bank | $98 → $115 | Maintains | Buy | |||
06/04/2025 | 9.3% | Goldman Sachs | $94 → $104 | Maintains | Neutral | |||
06/04/2025 | 22.96% | RBC Capital | $112 → $117 | Maintains | Outperform | |||
06/04/2025 | 31.37% | B of A Securities | $110 → $125 | Maintains | Buy | |||
06/04/2025 | 22.96% | JMP Securities | $110 → $117 | Maintains | Market Outperform | |||
05/22/2025 | 17.71% | RBC Capital | $105 → $112 | Assumes | → Outperform | |||
04/16/2025 | 5.1% | Keybanc | $110 → $100 | Maintains | Overweight | |||
04/11/2025 | 17.71% | Barrington Research | $112 → $112 | Maintains | Outperform | |||
03/27/2025 | -1.21% | Goldman Sachs | $107 → $94 | Maintains | Neutral | |||
03/25/2025 | 20.86% | Raymond James | $120 → $115 | Upgrade | Outperform → Strong Buy | |||
03/24/2025 | 15.61% | Keybanc | $120 → $110 | Maintains | Overweight | |||
03/20/2025 | 3% | Deutsche Bank | $108 → $98 | Maintains | Buy | |||
03/19/2025 | 17.71% | Barrington Research | $112 → $112 | Maintains | Outperform | |||
03/14/2025 | 17.71% | Barrington Research | $112 → $112 | Maintains | Outperform | |||
02/26/2025 | 31.37% | Wells Fargo | $110 → $125 | Maintains | Overweight | |||
02/25/2025 | 26.12% | Raymond James | $105 → $120 | Maintains | Outperform | |||
01/14/2025 | 13.5% | Deutsche Bank | $103 → $108 | Maintains | Buy | |||
12/10/2024 | 12.45% | JMP Securities | $105 → $107 | Maintains | Market Outperform | |||
12/10/2024 | 10.35% | RBC Capital | $100 → $105 | Maintains | Outperform | |||
12/04/2024 | 32.42% | Mizuho | → $126 | Initiates | → Outperform | |||
12/02/2024 | 24.01% | Jefferies | $95 → $118 | Maintains | Buy | |||
12/02/2024 | 26.12% | Barrington Research | $105 → $120 | Maintains | Outperform | |||
11/15/2024 | 13.5% | Goldman Sachs | → $108 | Initiates | → Neutral | |||
11/14/2024 | 36.63% | BTIG | $110 → $130 | Maintains | Buy | |||
11/13/2024 | 26.12% | B of A Securities | $100 → $120 | Maintains | Buy | |||
09/20/2024 | 10.35% | Barrington Research | $105 → $105 | Maintains | Outperform | |||
09/04/2024 | 10.35% | Barrington Research | $105 → $105 | Maintains | Outperform | |||
09/04/2024 | 8.25% | Deutsche Bank | $102 → $103 | Maintains | Buy | |||
09/04/2024 | 10.35% | JMP Securities | $105 → $105 | Reiterates | Market Outperform → Market Outperform | |||
09/04/2024 | -3.31% | RBC Capital | $92 → $92 | Reiterates | Outperform → Outperform | |||
09/04/2024 | 5.1% | B of A Securities | $105 → $100 | Maintains | Buy | |||
08/30/2024 | 10.35% | Barrington Research | $105 → $105 | Maintains | Outperform | |||
07/03/2024 | 10.35% | B of A Securities | $105 → $105 | Maintains | Buy | |||
06/20/2024 | 15.61% | Wells Fargo | $107 → $110 | Maintains | Overweight | |||
06/07/2024 | 10.35% | Raymond James | $100 → $105 | Maintains | Outperform | |||
06/05/2024 | 5.1% | Keybanc | $95 → $100 | Maintains | Overweight | |||
06/04/2024 | 12.45% | Wells Fargo | $105 → $107 | Maintains | Overweight | |||
06/04/2024 | 10.35% | Barrington Research | $100 → $105 | Maintains | Outperform | |||
06/04/2024 | -3.31% | RBC Capital | $92 → $92 | Reiterates | Outperform → Outperform | |||
06/04/2024 | 10.35% | B of A Securities | $97 → $105 | Maintains | Buy | |||
06/04/2024 | 10.35% | JMP Securities | $101 → $105 | Maintains | Market Outperform | |||
06/04/2024 | 9.3% | Baird | $98 → $104 | Maintains | Outperform | |||
04/04/2024 | 6.15% | JMP Securities | → $101 | Initiates | → Market Outperform | |||
04/02/2024 | 13.5% | JP Morgan | $86 → $108 | Maintains | Overweight | |||
03/28/2024 | -0.16% | Jefferies | $79 → $95 | Maintains | Buy | |||
03/22/2024 | -0.16% | Keybanc | $85 → $95 | Maintains | Overweight | |||
03/22/2024 | 5.1% | Barrington Research | → $100 | Maintains | Outperform | |||
03/20/2024 | 15.61% | BTIG | $100 → $110 | Maintains | Buy | |||
03/20/2024 | -3.31% | RBC Capital | $90 → $92 | Maintains | Outperform | |||
03/20/2024 | 1.94% | B of A Securities | $93 → $97 | Maintains | Buy | |||
02/23/2024 | -5.41% | RBC Capital | $77 → $90 | Maintains | Outperform | |||
02/23/2024 | 9.3% | Barclays | — | $84 → $104 | Maintains | Overweight | ||
12/13/2023 | -0.16% | Raymond James | $90 → $95 | Maintains | Outperform | |||
12/06/2023 | -2.26% | Wells Fargo | $89 → $93 | Maintains | Overweight | |||
12/04/2023 | -10.67% | Barrington Research | → $85 | Reiterates | Outperform → Outperform | |||
12/01/2023 | -23.28% | JP Morgan | $81 → $73 | Maintains | Overweight | |||
09/21/2023 | -8.57% | Baird | $79 → $87 | Upgrade | Neutral → Outperform | |||
09/07/2023 | -24.33% | Deutsche Bank | $71 → $72 | Maintains | Buy | |||
09/06/2023 | -10.67% | Barrington Research | $80 → $85 | Reiterates | Outperform → Outperform | |||
09/06/2023 | -19.08% | RBC Capital | $75 → $77 | Maintains | Outperform | |||
06/07/2023 | -25.38% | Deutsche Bank | $69 → $71 | Maintains | Buy | |||
06/06/2023 | -21.18% | RBC Capital | → $75 | Reiterates | → Outperform | |||
06/01/2023 | -15.92% | Barrington Research | → $80 | Reiterates | Outperform → Outperform | |||
03/24/2023 | -27.48% | Deutsche Bank | $72 → $69 | Maintains | Buy | |||
03/22/2023 | -15.92% | Barrington Research | → $80 | Reiterates | → Outperform | |||
03/22/2023 | -21.18% | RBC Capital | → $75 | Reiterates | → Outperform | |||
02/03/2023 | -6.46% | Wells Fargo | $101 → $89 | Maintains | Overweight | |||
01/24/2023 | -24.33% | Deutsche Bank | $68 → $72 | Maintains | Buy | |||
12/12/2022 | -10.67% | Raymond James | $75 → $85 | Maintains | Outperform | |||
12/07/2022 | -1.21% | Guggenheim | $89 → $94 | Maintains | Buy | |||
12/07/2022 | 6.15% | Wells Fargo | $104 → $101 | Maintains | Overweight | |||
12/05/2022 | -21.18% | RBC Capital | $70 → $75 | Maintains | Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de HealthEquity (HQY)?
El último precio objetivo de HealthEquity (NASDAQ:HQY) fue comunicado por Keybanc el octubre 8, 2025. La firma de analistas fijó un precio objetivo para $120.00 que espera HQY a rise dentro de 12 meses (un posible 26.12% upside). 35 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre HealthEquity (HQY)?
La última calificación de analistas para HealthEquity (NASDAQ:HQY) fue proporcionada por Keybanc, y HealthEquity mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de HealthEquity (HQY)?
La última revisión al alza de HealthEquity Inc se produjo en marzo 25, 2025, cuando Raymond James elevó su precio objetivo a $115. Raymond James anteriormente tenía an outperform para HealthEquity Inc.
¿Cuándo fue la última revisión a la baja de HealthEquity (HQY)?
No hay una última revisión a la baja para HealthEquity.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para HealthEquity (HQY)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de HealthEquity, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de HealthEquity se registró el octubre 8, 2025, por lo que la próxima calificación estará disponible en torno al octubre 8, 2026.
¿Es correcta la calificación de los analistas sobre HealthEquity (HQY)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de HealthEquity (HQY) fue un mantuvo con un precio objetivo de $125.00 a $120.00. El precio actual al que cotiza HealthEquity (HQY) es de $95.15, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.